Data from: Small molecule protein assembly modulators with Pan-Cancer therapeutic efficacy

Two structurally-unrelated small molecule chemotypes, represented by
compounds PAV-617 and PAV-951 with antiviral activity in cell culture
against Mpox virus (Formerly known as monkeypox virus) and human
immunodeficiency virus (HIV) respectively, were studied for anti-cancer
efficacy. Each exhibited apparent pan-cancer cytotoxicity, reasonable
pharmacokinetics, and non-toxicity in mice at active concentrations.
Anti-tumor properties of both chemotypes were validated in mouse
xenografts against A549 human lung cancer and, for one of the chemotypes
against HT-29 colorectal cancer. The targets of these compounds are
unconventional: each binds to a different transient, energy-dependent
multi-protein complex. Treatment with these compounds alters the target
multi-protein complexes in a manner that appears to remove a block,
crucial for cancer survival and progression, on a homeostatic linkage
between uncontrolled proliferation and apoptosis. These compounds provide
starting points for development of novel, next-generation, non-toxic,
pan-cancer therapeutics.